title: Comparing Two Types of Rabbit ATG prior to Reduced Intensity Conditioning Allogeneic Hematopoietic SCT for Hematologic Malignancies.
abstract: Different rabbit polyclonal antilymphocyte globulins (ATGs) are used in allogeneic hematopoietic stem cell transplantation (alloHSCT) to prevent graft-versus-host disease (GvHD). We compared 2 different ATGs in alloHSCT after reduced intensity conditioning (RIC) for hematological malignancies. We reviewed 30 alloHSCT for hematologic malignancies performed between 2007 and 2010 with fludarabine and i.v. busulfan as conditioning regimen. Patients alternatingly received Thymoglobulin or ATG-F. Median followup was 3.3 (2.5-4.5) years. Adverse events appeared to occur more frequently during Thymoglobulin infusion than during ATG-F infusion but without statistical significance (P = 0.14). There were also no differences in 3-year overall survival (OS), disease-free survival (DFS), relapse incidence, and transplant related mortality (TRM) in the Thymoglobulin versus ATG-F group: 45.7% versus 46.7%, 40% versus 33.7%, 40% versus 33.3%, and 20% versus 33.3%. The same held for graft failure, rejection, infectious complications, immune reconstitution, and acute or chronic GvHD. In patients transplanted for hematologic malignancies after RIC, the use of Thymoglobulin is comparable to that of ATG-F in all the aspects evaluated in the study. However due to the small number of patients in each group we cannot exclude a possible difference that may exist.
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Sandra
authors: 0000-0002-0529-4875
authors: S
authors: Paiano
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Eddy
authors: E
authors: Roosnek
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Yordanka
authors: Y
authors: Tirefort
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Monika
authors: M
authors: Nagy-Hulliger
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Stavroula
authors: S
authors: Masouridi
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Emmanuel
authors: E
authors: Levrat
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Michael
authors: M
authors: Bernimoulin
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Saadia
authors: S
authors: Huguet
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Alessandro
authors: A
authors: Casini
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Thomas
authors: T
authors: Matthes
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Kaveh
authors: K
authors: Samii
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Jakob R
authors: JR
authors: Passweg
authors: Division of Hematology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.
authors: Yves
authors: 0000-0001-9341-8104
authors: Y
authors: Chalandon